Last reviewed · How we verify
Cisplatin,fluorouracil
Cisplatin and fluorouracil work together as DNA-damaging chemotherapy agents that inhibit cancer cell proliferation and induce apoptosis.
Cisplatin and fluorouracil work together as DNA-damaging chemotherapy agents that inhibit cancer cell proliferation and induce apoptosis. Used for Advanced or metastatic gastric cancer, Head and neck cancer, Colorectal cancer.
At a glance
| Generic name | Cisplatin,fluorouracil |
|---|---|
| Also known as | Cisplatin and fluorouracil |
| Sponsor | Sun Yat-sen University |
| Drug class | Chemotherapy combination (platinum agent + antimetabolite) |
| Target | DNA (direct cross-linking and antimetabolite incorporation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing replication and transcription. Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting nucleotide synthesis. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Advanced or metastatic gastric cancer
- Head and neck cancer
- Colorectal cancer
- Esophageal cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Mucositis
- Diarrhea
- Alopecia
Key clinical trials
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (PHASE2)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE1)
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |